Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes

Vincent M Monnier, Wanjie Sun, Xiaoyu Gao, David R Sell, Patricia A Cleary, John M Lachin, Saul Genuth, DCCT/EDIC Research Group, Vincent M Monnier, Wanjie Sun, Xiaoyu Gao, David R Sell, Patricia A Cleary, John M Lachin, Saul Genuth, DCCT/EDIC Research Group

Abstract

Background: We recently reported strong associations between eight skin collagen AGEs and two solubility markers from skin biopsies obtained at DCCT study closeout and the long-term progression of microvascular disease in EDIC, despite adjustment for mean glycemia. Herein we investigated the hypothesis that some of these AGEs (fluorescence to be reported elsewhere) correlate with long-term subclinical cardiovascular disease (CVD) measurements, i.e. coronary artery calcium score (CAC) at EDIC year 7-9 (n = 187), change of carotid intima-media thickness (IMT) from EDIC year 1 to year 6 and 12 (n = 127), and cardiac MRI outcomes at EDIC year 15-16 (n = 142).

Methods: Skin collagen AGE measurements obtained from stored specimens were related to clinical data from the DCCT/EDIC using Spearman correlations and multivariable logistic regression analyses.

Results: Spearman correlations showed furosine (early glycation) was associated with future mean CAC (p < 0.05) and CAC >0 (p = 0.039), [corrected] but not with CAC score <100 vs. >100. Glucosepane and pentosidine crosslinks, methylglyoxal hydroimidazolones (MG-H1) and pepsin solubility (inversely) correlated with IMT change from year 1 to 6(all P < 0.05). Left ventricular (LV) mass (cMRI) correlated with MG-H1, and inversely with pepsin solubility (both p < 0.05), while the ratio LV mass/end diastolic volume correlated with furosine and MG-H1 (both p < 0.05), and highly with CML (p < 0.01). In multivariate analysis only furosine (p = 0.01) was associated with CAC. In contrast IMT was inversely associated with lower collagen pepsin solubility and positively with glucosepane,

Conclusions: In type 1 diabetes, multiple AGEs are associated with IMT progression in spite of adjustment for A1c implying a likely participatory role of glycation and AGE mediated crosslinking on matrix accumulation in coronary arteries. This may also apply to functional cardiac MRI outcomes, especially left ventricular mass. In contrast, early glycation measured by furosine, but not AGEs, was associated with CAC score, implying hyperglycemia as a risk factor in calcium deposition perhaps via processes independent of glycation.

Trial registration: Registered at Clinical trial reg. nos. NCT00360815 and NCT00360893, http://www.clinicaltrials.gov.

References

    1. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294–2303. doi: 10.1056/NEJMoa022314.
    1. Turkbey EB, Jye-Yu C, Backlund M, Genuth S, Jain A, Miao C, et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation. 2011;124:1737–1746. doi: 10.1161/CIRCULATIONAHA.111.022327.
    1. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48:870–880. doi: 10.2337/diabetes.48.4.870.
    1. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54:3103–3111. doi: 10.2337/diabetes.54.11.3103.
    1. Genuth S, Sun W, Cleary P, Gao X, Sell DR, Lachin J, et al. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes. 2015;64:266–278. doi: 10.2337/db14-0215.
    1. Monnier VM, Sell DR, Strauch C, Sun W, Lachin JM, Cleary PA, et al. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J Diabetes Complicat. 2013;27:141–149. doi: 10.1016/j.jdiacomp.2012.10.004.
    1. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006;55:3556–3565. doi: 10.2337/db06-0653.
    1. Tobin J. Estimation of relationships for limited dependent variables. Econometrica. 1958;26:24–36. doi: 10.2307/1907382.
    1. SAS Institute I (1995) SAS/STAT User’s guide, version 8. SAS Institute Inc, Cary
    1. Lachin J. Biostatistical Methods: the assessment of relative risks. New York: Wiley; 2000.
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B. 1995;54:289–300.
    1. DCCT/EDIC Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381–389. doi: 10.1056/NEJM200002103420603.
    1. van Eupen MG, Schram MT, Colhoun HM, Scheijen JL, Stehouwer CD, Schalkwijk CG. Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification. Cardiovasc Diabetol. 2013;12:149. doi: 10.1186/1475-2840-12-149.
    1. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, et al. Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis. 2012;221:387–396. doi: 10.1016/j.atherosclerosis.2012.01.019.
    1. Nagaraj RH, Sell DR, Prabhakaram M, Ortwerth BJ, Monnier VM. High correlation between pentosidine protein crosslinks and pigmentation implicates ascorbate oxidation in human lens senescence and cataractogenesis. Proc Natl Acad Sci USA. 1991;88:10257–10261. doi: 10.1073/pnas.88.22.10257.
    1. Liberman M, Johnson RC, Handy DE, Loscalzo J, Leopold JA. Bone morphogenetic protein-2 activates NADPH oxidase to increase endoplasmic reticulum stress and human coronary artery smooth muscle cell calcification. Biochem Biophys Res Commun. 2011;413:436–441. doi: 10.1016/j.bbrc.2011.08.114.
    1. Sell DR, Biemel KM, Reihl O, Lederer MO, Strauch CM, Monnier VM. Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes. J Biol Chem. 2005;280:12310–12315. doi: 10.1074/jbc.M500733200.
    1. Sveen KA, Dahl-Jorgensen K, Stensaeth KH, Angel K, Seljeflot I, Sell DR, et al. Glucosepane and oxidative markers in skin collagen correlate with intima media thickness and arterial stiffness in long-term type 1 diabetes. J Diabetes Complications. 2015;29:407–412. doi: 10.1016/j.jdiacomp.2014.12.011.
    1. Hanssen NM, Beulens JW, van Dieren S, Scheijen JL, van der A DL, Spijkerman AM, et al. Plasma advanced glycation endproducts are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL) Diabetes. 2015;64:257–265. doi: 10.2337/db13-1864.
    1. Hu S, He W, Liu Z, Xu H, Ma G. The accumulation of the glycoxidation product N(epsilon)-carboxymethyllysine in cardiac tissues with age, diabetes mellitus and coronary heart disease. Tohoku J Exp Med. 2013;230:25–32. doi: 10.1620/tjem.230.25.
    1. Kizer JR, Benkeser D, Arnold AM, Ix JH, Mukamal KJ, Djousse L, et al. Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults. Atherosclerosis. 2014;235:116–121. doi: 10.1016/j.atherosclerosis.2014.04.013.
    1. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676–683. doi: 10.2337/diab.43.5.676.
    1. Cooper GJ, Young AA, Gamble GD, Occleshaw CJ, Dissanayake AM, Cowan BR, et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia. 2009;52:715–722. doi: 10.1007/s00125-009-1265-3.
    1. Cooper GJ. Selective divalent copper chelation for the treatment of diabetes mellitus. Curr Med Chem. 2012;19:2828–2860. doi: 10.2174/092986712800609715.
    1. Frye EB, Degenhardt TP, Thorpe SR, Baynes JW. Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem. 1998;273:18714–18719. doi: 10.1074/jbc.273.30.18714.
    1. Chong SA, Lee W, Arora PD, Laschinger C, Young EW, Simmons CA, et al. Methylglyoxal inhibits the binding step of collagen phagocytosis. J Biol Chem. 2007;282:8510–8520. doi: 10.1074/jbc.M609859200.
    1. Sassi-Gaha S, Loughlin DT, Kappler F, Schwartz ML, Su B, Tobia AM, et al. Two dicarbonyl compounds, 3-deoxyglucosone and methylglyoxal, differentially modulate dermal fibroblasts. Matrix Biol J Int Soc Matrix Biol. 2010;29:127–134. doi: 10.1016/j.matbio.2009.09.007.
    1. Yuen A, Laschinger C, Talior I, Lee W, Chan M, Birek J, et al. Methylglyoxal-modified collagen promotes myofibroblast differentiation. Matrix Biol J Int Soc Matrix Biol. 2010;29:537–548. doi: 10.1016/j.matbio.2010.04.004.
    1. Paul RG, Bailey AJ. The effect of advanced glycation end-product formation upon cell-matrix interactions. Int J Biochem Cell Biol. 1999;31:653–660. doi: 10.1016/S1357-2725(99)00023-0.
    1. Dobler D, Ahmed N, Song L, Eboigbodin KE, Thornalley PJ. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes. 2006;55:1961–1969. doi: 10.2337/db05-1634.
    1. Golej J, Hoeger H, Radner W, Unfried G, Lubec G. Oral administration of methylglyoxal leads to kidney collagen accumulation in the mouse. Life Sci. 1998;63:801–807. doi: 10.1016/S0024-3205(98)00336-1.
    1. Sveen KA, Nerdrum T, Hanssen KF, Brekke M, Torjesen PA, Strauch CM, et al. Impaired left ventricular function and myocardial blood flow reserve in patients with long-term type 1 diabetes and no significant coronary artery disease: associations with protein glycation. Diab Vasc Dis Res. 2014;11:84–91. doi: 10.1177/1479164113518805.
    1. Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care. 2011;34:968–974. doi: 10.2337/dc10-1675.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi